GM-CSF Versus G-CSF in the treatment of infectious complication in Felty's syndrome — a case report

Ulrich Kaiser(University of Applied Sciences Landshut), K.-H. Pflüger, Martine Klausmann(Praxis für Hämatologie und Onkologie), Götz M. Richter(Yeshiva University)

Annals of Hematology

April 1, 1992

10.1007/bf01696225

Cited by 10

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Nature and significance of endoleaks and endotension: Summary of opinions expressed at an international conference

|Journal of Vascular Surgery|2002|616

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

|Blood|2021|170